Compass Pathways PLC (CMPS) — SEC Filings
Compass Pathways PLC (CMPS) — 28 SEC filings. Latest: S-8 (Mar 24, 2026). Includes 11 8-K, 5 10-Q, 3 10-K.
View Compass Pathways PLC on SEC EDGAR
Overview
Compass Pathways PLC (CMPS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 24, 2026: COMPASS Pathways plc filed an S-8 on March 24, 2026, to register securities for its employee benefit plans. This filing, under File No. 333-294572, allows the company to issue shares to employees, which can be a way to attract and retain talent. For investors, this matters because it indicates poten
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 2 mixed. The dominant filing sentiment for Compass Pathways PLC is neutral.
Filing Type Overview
Compass Pathways PLC (CMPS) has filed 1 S-8, 3 10-K, 11 8-K, 5 10-Q, 2 DEF 14A, 3 SC 13G/A, 1 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of CMPS's 19 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- GoldsmithMember
- NathMember
- Ryan Barrett
- David Norton
- George Goldsmith
- Dr. Guy Goodwin
Industry Context
The mental health therapeutics market is undergoing significant innovation, with a growing interest in novel treatment modalities beyond traditional pharmaceuticals. Biotechnology companies are exploring psychedelic compounds, like psilocybin, for their potential to offer rapid and durable responses for conditions with high unmet needs. However, the development pathway is complex, involving rigorous clinical trials, regulatory hurdles, and the need for new treatment paradigms and reimbursement models.
Top Tags
Biotechnology (3) · Mental Health (3) · Clinical Trials (3) · 8-K (3) · corporate-governance (3) · executive-compensation (3) · 10-Q (3) · financials (3) · COMPASS Pathways (3) · Psilocybin (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | $0 | No revenue generated for the fiscal year ended December 31, 2025, indicating pre-commercial stage. |
| COMP360 dose | 25mg | Demonstrated statistically significant efficacy in Phase 2b TRD trial. |
| Patients in COMP005 | 258 | Enrollment completed for pivotal Phase 3 TRD trial 1. |
| Patients in COMP006 | 581 | Enrollment completed for pivotal Phase 3 TRD trial 2. |
| Year | 2018 | Received FDA Breakthrough Therapy designation for COMP360 in TRD. |
| Market Value | $257.1 million | Aggregate market value of non-affiliate shares as of June 30, 2025. |
| Shares Outstanding | 128,923,295 | Common stock outstanding as of March 17, 2025. |
| Net Loss | $193.98M | Increased from $111.79M for the nine months ended September 30, 2024 |
| Fair Value Change of Warrant Liabilities | $84.40M | Primary driver of increased net loss for the nine months ended September 30, 2025 |
| Cash and Cash Equivalents | $185.94M | Increased from $165.08M at December 31, 2024 |
| Total Liabilities | $218.02M | Increased from $58.97M at December 31, 2024, largely due to warrant liabilities |
| Warrant Liabilities | $165.56M | New liability as of September 30, 2025, contributing to increased total liabilities |
| Research and Development Expenses | $88.53M | Slightly increased from $86.90M for the nine months ended September 30, 2024 |
| Net Loss Per Share (Q3 2025) | $1.44 | Increased from $0.56 in Q3 2024 |
| Net Loss Per Share (YTD 2025) | $2.09 | Increased from $1.67 in YTD 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Compass Pathways PLC (CMPS)?
Compass Pathways PLC has 28 recent SEC filings from Jan 2024 to Mar 2026, including 11 8-K, 5 10-Q, 3 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CMPS filings?
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 24 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Compass Pathways PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Compass Pathways PLC (CMPS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Compass Pathways PLC?
Key financial highlights from Compass Pathways PLC's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CMPS?
The investment thesis for CMPS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Compass Pathways PLC?
Key executives identified across Compass Pathways PLC's filings include GoldsmithMember, NathMember, Ryan Barrett, David Norton, George Goldsmith and 1 others.
What are the main risk factors for Compass Pathways PLC stock?
Of CMPS's 19 assessed filings, 3 were flagged high-risk, 6 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Compass Pathways PLC?
Forward guidance and predictions for Compass Pathways PLC are extracted from SEC filings as they are enriched.